Table 2.

Summary of literature reporting overall survival related to CNS tumors in clinical trials, split by ages <3 y and 3–14 y

	Tumor Type	Survival, %
		Trials22,24,26,27,29,30,42–57	Present Study
<3 y	Low-grade glioma (WHO grades I/II)	5y 95 (1–3 y old, 95 <1 y old, 76)
	High-grade glioma (WHO grades III/IV)	5y 31–66	SEER 5y 51
		10y 38	NRCT 5y 35
			SEER 10y 51
			NRCT 10y 35
	Ependymoma	5y 63	SEER 5y 67
			NRCT 5y 56
			SEER 10y 62
			NRCT 10y 49
	Embryonal (medulloblastoma, sPNET)		SEER 5y 48
			NRCT 5y 33
	Medulloblastoma	5y 43	SEER 5y 52
			NRCT 5y 42
			SEER 10y 49
			NRCT 10y 42
	sPNET	5y 31	SEER 5y 43
			NRCT 5y 11
			SEER 10y 41
			NRCT 10y 11
3–14 y	Low-grade glioma (WHO grades I/II)	5y 86
		10y 94
	High-grade glioma (WHO grades III/IV)	2y 21	SEER 2y 22
		5y 19	NRCT 2y 13
			SEER 5y 22
			NRCT 5y 10
	Ependymoma	5y 60–85	SEER 5y 76
			NRCT 5y 71
			SEER 10y 74
			NRCT 10y 63
	Embryonal (medulloblastoma, sPNET)		SEER 5y 73
			NRCT 5y 67
	Medulloblastoma	5y 87	SEER 5y 76
		10y 81	NRCT 5y 71
			SEER 10y 74
			NRCT 10y 64
	sPNET	5y 73	SEER 5y 65
			NRCT 5y 45
			SEER 10y 61
			NRCT 10y 36

Abbreviation: WHO, World Health Organization.